Study guide

Safe Handling, PPE, Occupational Health, and Exposure Response

OCN Oncology Certified Nurse Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: OCN Exam Orientation and Official Source Control

Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness

2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care

Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures

3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment

Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation

4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards

Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development

5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy

Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation

6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents

Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation

7 Chapter 7: Symptom Management and Supportive Care

Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination

8 Chapter 8: Oncologic Emergencies and Rapid Escalation

Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

9 Chapter 9: Psychosocial Dimensions of Oncology Care

Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals

10 Chapter 10: Mixed OCN Case Labs

New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab

11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness

Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning

Safe Handling, PPE, Occupational Health, and Exposure Response

Key Takeaways Explain This Topic AI

Hazardous drug precautions protect nurses, patients, caregivers, and the environment across receipt, storage, preparation, administration, disposal, and spill response.

USP General Chapter <800> and the NIOSH 2024 Hazardous Drug List drive policy; administering injectable antineoplastic drugs requires two pairs of chemotherapy gloves and a gown shown to resist HD permeability.

Exposure response requires immediate decontamination first, then prompt reporting, occupational health evaluation, and documentation.

Engineering controls and work-practice controls sit above PPE in the hierarchy of controls; PPE alone cannot fix unsafe workflow.

Last updated: October 2026

  • Safe Handling, PPE, Occupational Health, and Exposure Response
  • Hazardous drug risk in oncology

Many antineoplastic and related agents are hazardous drugs (HDs) because they may be carcinogenic, genotoxic, teratogenic, toxic to reproduction, or organ-toxic at low doses. Exposure occurs through skin contact, inhalation, ingestion, accidental injection, contaminated surfaces, spills, priming tubing, disconnecting lines, crushing tablets, handling contaminated body fluids (treat excreta as contaminated for 48 hours after most regimens per policy), and waste disposal.

OCN candidates must think well beyond the moment of infusion: safe handling begins when the drug enters the organization and continues through storage, compounding, transport, administration, disposal, cleaning, and post-administration patient care.

USP General Chapter <800> , the NIOSH 2024 List of Hazardous Drugs in Healthcare Settings (which replaced the 2016 list in December 2024), OSHA standards, and organizational policy support a hierarchy of controls that reduces exposure before relying on individual behavior.

Control level Examples (most to least protective)

Engineering Biological safety cabinets, containment isolators, closed-system drug-transfer devices (CSTDs), negative-pressure compounding rooms, sharps-safety devices.

Work practice No eating/drinking in handling areas, no clipping contaminated tubing, safe priming, luer-lock connections, HD labeling, avoiding aerosols.

PPE Two pairs of chemotherapy gloves, tested impervious gown, eye/face and respiratory protection by task.

PPE for oncology tasks

PPE must match the task and policy. For administering injectable antineoplastic HDs, USP <800> requires two pairs of chemotherapy gloves (ASTM D6978) and a disposable gown shown to resist HD permeability that closes in the back (no open front) and has closed elastic or knit cuffs. For intact tablets and capsules, NIOSH lists a single pair of chemotherapy gloves; PPE for other dosage forms and tasks follows facility policy. Eye and face protection are added when splashing is possible; respiratory protection (a fit-tested N95 or higher) is required for spill, aerosol, or powder risk. Replace gloves about every 30 minutes or immediately when torn or contaminated, and gowns about every 2 to 3 hours or when soiled.

Task Typical protection focus

IV antineoplastic administration Two pairs chemotherapy gloves, tested gown, closed connections, safe disposal in yellow HD waste.

Oral hazardous drug handling Avoid bare-hand contact, glove up; do not crush or split unless pharmacy/policy explicitly allow.

Body fluid handling after therapy Gloves and gown when contact is likely; follow facility time frames and waste rules.

Spill response Trained staff only, spill kit, PPE per policy, area control, cleanup, reporting.

Patients and caregivers also need practical education: handling oral HDs, storing them away from children and pets, not loading tablets into pill organizers without guidance, returning unused drug properly, gloving for contaminated linens or excreta when advised, and whom to call after accidental exposure. Document this teaching.

Bloodborne pathogens and infection exposure

Oncology nurses also face bloodborne pathogen risk from central-line access, phlebotomy, injections, drains, wounds, and sharps. Standard precautions apply to every patient because infection status may be unknown. The OSHA Bloodborne Pathogens Standard (29 CFR 1910.1030) requires an exposure control plan, safer-engineered devices, training, PPE, an offered hepatitis B vaccination, post-exposure evaluation, and recordkeeping.

In practice: use safety needles, activate sharps protection immediately, never recap by hand unless an approved exception applies, dispose of sharps at the point of use, and wear PPE whenever blood or body-fluid exposure is reasonably anticipated.

Exposure and spill response

For any HD splash, needlestick, or mucous-membrane exposure, decontaminate first, then report . For skin exposure, remove contaminated PPE/clothing and wash with soap and water. For eye exposure, flush at an eyewash station for the time specified by policy (commonly at least 15 minutes). For a needlestick, wash the site, report promptly, and follow occupational-health evaluation. Do not wait until shift end; early reporting enables medical evaluation, source assessment, post-exposure prophylaxis decisions, documentation, and process improvement.

Spill response follows the facility spill plan. Priorities in order: protect people, restrict the area, retrieve the spill kit, don required PPE, clean per kit instructions, dispose of waste as HD waste, and report. Untrained staff must not improvise cleanup. A large spill, powder aerosolization, broken glass, or eye/skin contact may require pharmacy, environmental services, employee health, or safety-officer support.

Safety culture

Safe handling is sustained by training, competency validation, audits, clear labeling, accessible spill kits, adequate staffing, and leadership support. Nurses should report missing PPE, unsafe workflow, contaminated surfaces, leaking connections, and unclear policies. For the exam, remember worker safety and patient safety are linked: a nurse who shortcuts PPE, skips a double check, or hides an exposure weakens the whole safety system.

Extravasation: a handling emergency

Extravasation (leakage of a vesicant into surrounding tissue) is the classic oncology handling emergency and a frequent exam topic. At the first sign of swelling, burning, redness, leaking, loss of blood return, or resistance, stop the infusion immediately, leave the catheter in place, and aspirate residual drug before removing it. Notify the provider, follow the antidote and thermal protocol, and document the site, estimated volume, symptoms, and interventions with photographs when policy allows.

Thermal management is agent-specific: cold compresses for most vesicants such as doxorubicin, but warm compresses and hyaluronidase for vinca alkaloids. Applying the wrong temperature can worsen injury, which is a common distractor.

Waste segregation and environmental health

Hazardous-drug waste is not regular trash. Trace-contaminated items (empty bags, tubing, PPE) go in yellow HD waste , while bulk or RCRA-listed agents may require black hazardous-waste containers. Sharps go to point-of-use sharps containers. Mixing HD waste with regular or red biohazard waste is a compliance failure that surveyors flag. Environmental health, a Standard of Professional Performance, also covers safe storage temperatures, segregated HD receiving and storage areas, and deactivation/decontamination of work surfaces with appropriate agents.

Reproductive and vulnerable-worker protections

USP <800> recognizes that some HDs are reproductive toxins. Policies should allow staff who are pregnant, trying to conceive, or breastfeeding to review the NIOSH list and request alternative duty without penalty. The exam may present a pregnant nurse asked to administer a known teratogen; the correct response respects the organization's reproductive-safety policy rather than dismissing the risk or refusing all assignments outright.